Serum Calcitonin Gene-Related Peptide Concentrations in CADASIL Patients


About this study

The aim of this investigation is to determine if patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) have elevated serum concentrations of calcitonin gene-related peptide (CGRP) which may be relevant for future therapeutic considerations within this patient population.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years old, known diagnosis of CADASIL or history of migraine

Exclusion Criteria: 

  • Under the age of 18 years old
  • Patients with competing intracerebral pathology (e.g. history of intracerebral hemorrhage, multiple sclerosis)
  • Use of migraine abortive agent within 1 week of serum collection
  • Significant cardiac disease with impaired ejection fraction
  • Pregnancy or breastfeeding

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

James Klaas, M.D.

Closed for enrollment

Jacksonville, Fla.

Mayo Clinic principal investigator

Josephine Huang, M.D.

Closed for enrollment

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

David Dodick, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer